Navigation Links
ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
Date:10/25/2008

ard effective dose regimen of methotrexate alone.

In both studies, nearly one-third of all ACTEMRA (8 mg/kg) patients achieved disease remission (as defined by DAS28 <2.6(2)) and ACTEMRA was generally well-tolerated compared with existing therapies.

About the RADIATE Study

RADIATE (RheumAtoiD ArthritIs Study in Anti-TNF FailurEs), a three-arm, randomized, double-blind, placebo-controlled study, was designed to evaluate the safety and efficacy of ACTEMRA plus methotrexate compared with placebo plus methotrexate in patients who failed to adequately respond to anti-TNF-alpha medications alone.? Between 13-17 percent of the study population experienced three or more prior anti-TNF-alpha failures. Patients were randomized to receive either ACTEMRA intravenously (4 mg/kg or 8 mg/kg) plus methotrexate every four weeks or placebo infusions plus methotrexate weekly for 24 weeks. The study included nearly 500 patients from 128 sites in 13 countries, including the United States. In the study, 50 percent, 29 percent and 12 percent of RA patients treated with ACTEMRA 8 mg/kg plus methotrexate achieved ACR20, ACR50 and ACR70, respectively, and 30 percent, 17 percent and 5 percent of patients in the ACTEMRA 4 mg/kg arm achieved these ACR scores, respectively. In contrast, 10 percent, 4 percent and 1 percent of patients in the control group achieved ACR20, ACR50 and ACR70, respectively. Furthermore, disease remission (DAS28 <2.6) was demonstrated in 30 percent and 8 percent of patients treated with ACTEMRA 8 mg/kg and 4 mg/kg, respectively, compared with 1.6 percent of patients in the control group.

Treatment with ACTEMRA and methotrexate showed significant clinical benefits even in the subgroup analysis of difficult-to-treat patients who received up to three anti-TNF-alpha therapies that failed.

The most common adverse reactions reported most frequently in the ACTEMRA arms of the RADIATE study were diarrhea, upper abdominal pain, rash and dizzine
'/>"/>

SOURCE Hoffmann-La Roche Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
4. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
5. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
6. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
7. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
8. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
9. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
10. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
11. New Study: Pine Bark Significantly Reduces Menstrual Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... N.Y. , Oct. 19, 2014  Henry Schein, ... provider of health care products and services to office-based ... it has invested in Iwase Dental Supply, Inc., a ... in Japan.  The transaction marks Henry Schein,s entrance into ... largest dental market, and increases to 28 the number ...
(Date:10/17/2014)... N.C. , Oct. 17, 2014 ... the Medical Affairs function has come across several ... resources efficiently and managing globalization.  ... Practices, LLC is dedicated to providing benchmarking and ... Medical Affairs Consortium is a service composed of ...
(Date:10/17/2014)... OAKS, Calif. , Oct. 17, 2014  Amgen ... of R. Sanders Williams , M.D., president of ... Mahley Distinguished Professor.  "We are pleased ... Amgen Board," said Robert A. Bradway , chairman ... and distinguished experience in academic medicine and his direct ...
Breaking Medicine Technology:Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Early Key Findings from the Medical Affairs Consortium Research 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3
... 12 ,Micromet, Inc. (Nasdaq: MITI ) and ... treatment in a multi-center, phase 2 trial conducted ... adult acute lymphoblastic leukemia (ALL). Blinatumomab is a ... is only expressed,on B cells. The clinical development ...
... June 11 /Xinhua-PRNewswire-FirstCall/ --,Pharmaceutical company Pharmaxis (ASX: PXS; ... III clinical trial evaluating the safety of,Bronchitol in ... 12-month treatment period was an open label extension ... reported, showing that Bronchitol,improved quality of life and ...
Cached Medicine Technology:Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 2Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 3Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 4Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 5Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 6Pharmaxis Long-Term Safety Study of Bronchitol Completes 2
(Date:10/20/2014)... Washington, D.C. (PRWEB) October 20, 2014 Zereana ... was crowned Mrs. Maryland 2014 on a platform to think ... battle scars, and uses her position to raise awareness about ... on awareness for breast cancer. You say the color pink ... “But I know for a fact that it has not ...
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... Collins, CO (PRWEB) October 20, 2014 ... dGH assays are the only imaging assays capable ... in a single test.  With these three dimensions ... their ability to detect the widest range of ... translocations—mutations usually missed by other genomic tools, including ...
(Date:10/20/2014)... hard to imagine what it’s like to live without shoes, ... it’s a reality. And while new shoes are considered a ... barefoot on rocky terrain or sewage-lined streets just to collect ... , Buckner International's Shoes for Orphan Souls project ... encourage support for Air1 and while also providing new shoes ...
(Date:10/19/2014)... and Hastings, a Phoenix personal injury law firm with ... area and across Arizona reports record demand in 2014 ... Statistics have indicated a steady increase in automobile accidents ... and Hastings has seen a steady increase in the ... injured through no fault of their own that is ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3
... Medicare Claims Denials by 50% and IVANS LIME Is Ten Times ... ... 18, 2009 -- IVANS , the leading provider of corporate ... Verification solution has helped Mobile X-Ray Imaging Inc. significantly reduce ...
... DALLAS, Feb. 18 Every week more than 3,000 people in ... many find themselves with insufficient coverage or lack of insurance to ... , , The Limbs for Life Foundation ... and provide them with financial assistance to return to productive jobs ...
... their meat. Whether it,s rib eyes, pork chops or chicken ... country that more than 85 billion pounds of meat and ... a quarter of U.S. beef and pork is exported to ... the world,s largest consumer of meat, in Mexico, meat consumption ...
... pressure medication may be the key to preventing brain ... newly published study by researchers at Wake Forest University ... of an improved quality of life for cancer patients. ... a hypothesis from previous studies that a compound similar ...
... , A research group of the Universities of Granada ... food craving, an irresistible desire for eating certain foods (sweets, ... out by Professors Silvia Moreno Domnguez (University of ... and M Carmen Fernndez-Santaella ( University of Granada ...
... by Cop" (SBC) is a suicide method in which a ... an attempt to get oneself killed or injured by law ... Sciences examined the prevalence of this phenomenon among a ... SBC occurs at extremely high rates, with 36 percent of ...
Cached Medicine News:Health News:IVANS Helps Mobile X-Ray Imaging Inc. Reduce Its Costs for Uncompensated Care 2Health News:IVANS Helps Mobile X-Ray Imaging Inc. Reduce Its Costs for Uncompensated Care 3Health News:Limbs for Life Foundation to Host 8th Annual Fundraiser and Live Auction 2Health News:American Veterinary Medical Association: Weaving a Web for Food Safety 2Health News:Blood pressure compound may benefit brain tumor patients 2Health News:Blood pressure compound may benefit brain tumor patients 3Health News:Several studies prove self-banning certain foods may cause food craving 2Health News:'Suicide by cop' phenomenon occurring in over a third of North American shootings involving police 2
... The complete line of Surgical Access ...unlike ... ,The OnePort™ trocar system is actually four ... versatile, operationally flexible and clinically adaptive to ... options in disposability and bladed or dilating ...
... Surgical Access ...unlike any trocar system you've ... is actually four systems in one ... clinically adaptive to all of your needs., ... bladed or dilating tip styles, OnePort™ can ...
... Surgical Access ...unlike any trocar system you've ... is actually four systems in one ... clinically adaptive to all of your needs., ... bladed or dilating tip styles, OnePort™ can ...
... Pak contains: (1) 15mm obturator, ... (1) 12mm ENDOPATH thoracic trocar ... Pak contains: (1) 15mm obturator, ... ,FPK03 Thoracic Trocar Pak contains: ...
Medicine Products: